6567975c212eaade2e0ee266
|
2018
|
United Kingdom
|
Department for International D...evelopment
more
|
2018006218
|
204584-160
|
3
|
Zambia
|
South of Sahara
|
LDCs
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0
|
0.0666933
|
0
|
0
|
0
|
0.0666933
|
0
|
|
|
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
SHORT TERM POLICY RELEVANT RES...EARCH LOOKING AT CHOLERA CONTROL IN ZAMBIA
more
|
Short term policy relevant res...earch looking at Cholera control in Zambia
more
|
To make DFIDs Research agenda ...more responsive through the production of short term policy research that will address the needs of policy makers by providing them with primary evidence that can subsequently be used for policy analysis in such areas as Health, Education, Conflict, Cash Transfers, Aid Transparency, Tax Policy, Social Protection, Energy, Payment by Results, Economics and Innovation. Short term policy driver research studies will be commissioned in the following sectors and regions. A series of case studies will be developed for Higher Education covering Burma, Ghana, Pakistan and Sierra Leone. The information available on Electricity Access and Electricity Insecurity will be reviewed for India. A study will be undertaken on assessing the Cuban Model of Medical Education in sub-Saharan Africa. A review will be undertaken looking at Social Protection and Tax in South Asia and sub-Saharan Africa and Activity based Learning will be reviewed in Tamil Nadu, India.
more
|
|
12182
|
Medical research
|
|
I.2.a. Health, General
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
University, college or other t...eaching institution, research institute or think?tank
more
|
|
|
6567975f212eaade2e0ee267
|
2019
|
World Health Organisation
|
WHO Core Voluntary contributio...ns
more
|
2019002745
|
1.006
|
8
|
Myanmar
|
South & Central Asia
|
LDCs
|
ODA Grants
|
4
|
10
|
110
|
C01
|
0.00228485
|
0.00228485
|
0
|
0
|
0.00228485
|
0.00228485
|
|
|
|
|
Communicable diseases
|
Communicable diseases Other
|
100
|
CVCA_635_1.6 ANTIMICROBIAL RES...ISTANCE
more
|
CVCA_635_1.6 Antimicrobial res...istance
more
|
Antimicrobial resistance
|
0
|
12220
|
Basic health care
|
3.3
|
I.2.b. Basic Health
|
41143
|
World Health Organisation - co...re voluntary contributions account
more
|
WHO-CVCA
|
|
3.3
|
65679760212eaade2e0ee268
|
2019
|
United Kingdom
|
Department of Health and Soci...al Care
more
|
2019005058
|
16_136_111
|
3
|
Developing countries, unspecif...ied
more
|
Regional and Unspecified
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
D02
|
0
|
0.444726
|
0
|
0
|
0
|
0.444726
|
0
|
|
|
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
NIHR GLOBAL HEALTH RESEARCH UN...IT ON GENOMIC SURVEILLANCE OF ANTIMICROBIAL RESISTANCE
more
|
NIHR Global Health Research Un...it on Genomic Surveillance of Antimicrobial Resistance
more
|
A UK and low- and middle-incom...e country (LMIC) partnership that aims to establish expertise and local research capacity in the use of whole genome sequencing in LMICs in order to provide intelligent global surveillance of microbial pathogens and antimicrobial resistance.
more
|
|
12182
|
Medical research
|
|
I.2.a. Health, General
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
University, college or other t...eaching institution, research institute or think?tank
more
|
|
|
65679761212eaade2e0ee269
|
2019
|
UNFPA
|
UNFPA
|
2019003502
|
|
8
|
Lao People's Democratic Republ...ic
more
|
Far East Asia
|
LDCs
|
ODA Grants
|
4
|
10
|
110
|
C01
|
0.152888
|
0.152888
|
0
|
0
|
0.152888
|
0.152888
|
|
|
|
|
Classified as not health-speci...fic activity
more
|
|
100
|
POPULATION AND DEVELPMENT
|
Population and Develpment
|
By 2030, build on existing ini...tiatives to develop measurements of progress on sustainable development that complement gross domestic product, and support statistical capacity-building in developing countries
more
|
Population and Develpment
|
13010
|
Population policy and administ...rative management
more
|
|
I.3. Population Policies/Progr...ammes & Reproductive Health
more
|
|
|
|
|
17.9
|
65679761212eaade2e0ee26a
|
2019
|
United Kingdom
|
Department for Business, Energ...y and Industrial Strategy
more
|
2019003520
|
BBSRC_NS_BB/N004574/1
|
3
|
Developing countries, unspecif...ied
more
|
Regional and Unspecified
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0.0629955
|
0.0629955
|
0
|
0
|
0.125991
|
0.125991
|
0
|
0.125991
|
0
|
0
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
50
|
15ERADBTB
|
15ERADbTB
|
This project will further our ...understanding of a number of aspects of bovine tuberculosis. New approaches to disease control are urgently needed, and this project offers new avenues to the development of both improved vaccines (such as liveattenuated vaccines), as well as improved diagnostics.
more
|
|
31182
|
Agricultural research
|
|
III.1.a. Agriculture
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
University, college or other t...eaching institution, research institute or think?tank
more
|
|
|
65679764212eaade2e0ee26b
|
2019
|
United Kingdom
|
Department for Business, Energ...y and Industrial Strategy
more
|
2019003865
|
MRC_NS_MR/S000542/1
|
1
|
Developing countries, unspecif...ied
more
|
Regional and Unspecified
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
D02
|
0.337678
|
0.337678
|
0
|
0
|
0.337678
|
0.337678
|
0
|
0.337678
|
0
|
0
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
THE MYCOBACTERIUM TUBERCULOSIS... CELL ENVELOPE: UNRAVELLING COMPLEX CELL WALL ASSEMBLY, DEGRADATION AND RECYCLING PATHWAYS
more
|
The Mycobacterium tuberculosis... Cell Envelope: unravelling complex cell wall assembly, degradation and recycling pathways
more
|
Development of two communityba...sed interventions targeting inappropriate antibiotic dispensing and use behaviours in rural Vietnam
more
|
|
12182
|
Medical research
|
|
I.2.a. Health, General
|
11000
|
Donor Government
|
Donor Government
|
|
|
65679764212eaade2e0ee26c
|
2020
|
Australia
|
Australian Government
|
2019003978
|
INM031
|
3
|
Developing countries, unspecif...ied
more
|
Regional and Unspecified
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
B03
|
0.688118
|
0.688118
|
0
|
0
|
0.688118
|
0.688118
|
|
0.688118
|
0
|
0
|
Emergency projects (meeting ad...ditional funding needs)
more
|
|
100
|
REGIONAL SRH PREPOSITIONING
|
Regional SRH prepositioning
|
Funding under this initiative ...supports the United Nations Population Fund (UNFPA) to preposition Sexual and Reproductive Health (SRH) and Gender Based Violence (GBV) commodities across identified disaster-prone countries in the Asia-Pacific region, for rapid distribution in the event of humanitarian crises. Depending on local needs, commodities might include dignity kits (hygiene items, items for protection such as torches and whistles, sanitary supplies, clothes), reproductive health kits, tents and equipment necessary for maternity/delivery facilities, and safe spaces for women and girls. National prepositioning will occur in Fiji, Indonesia, Myanmar, Papua New Guinea, Philippines, Tonga and Vanuatu. Regional prepositioning in Brisbane and potentially other locations will also be explored. The total value of this initiative is $3 million over 4 years, starting 2015-16.
more
|
0
|
72010
|
Material relief assistance and... services
more
|
5.6,3.2,3.1,15.a,15.3,13.1,10....4
more
|
VIII.1. Emergency Response
|
41119
|
United Nations Population Fund
|
United Nations Population Fund
|
|
COVID-19
|
65679765212eaade2e0ee26d
|
2019
|
World Health Organisation
|
WHO Core Voluntary contributio...ns
more
|
2019002329
|
2.001
|
8
|
Democratic Republic of the Con...go
more
|
South of Sahara
|
LDCs
|
ODA Grants
|
4
|
10
|
110
|
C01
|
0.0036681
|
0.0036681
|
0
|
0
|
0.0036681
|
0.0036681
|
|
|
|
|
Other health problems
|
Non-communicable diseases
|
100
|
CVCA_235_2.1 NONCOMMUNICABLE D...ISEASES
more
|
CVCA_235_2.1 Noncommunicable d...iseases
more
|
Noncommunicable diseases
|
0
|
12310
|
NCDs control, general
|
3.4
|
I.2.c. Non-communicable diseas...es (NCDs)
more
|
41143
|
World Health Organisation - co...re voluntary contributions account
more
|
WHO-CVCA
|
|
3.4
|
65679767212eaade2e0ee26e
|
2019
|
UNFPA
|
UNFPA
|
2019003148
|
|
8
|
Bosnia and Herzegovina
|
Europe
|
UMICs
|
ODA Grants
|
4
|
10
|
110
|
C01
|
0.0961631
|
0.0961631
|
0
|
0
|
0.0961631
|
0.0961631
|
|
|
|
|
Classified as not health-speci...fic activity
more
|
|
100
|
POPULATION AND DEVELPMENT
|
Population and Develpment
|
By 2030, build on existing ini...tiatives to develop measurements of progress on sustainable development that complement gross domestic product, and support statistical capacity-building in developing countries
more
|
Population and Develpment
|
16062
|
Statistical capacity building
|
|
I.6. Other Social Infrastructu...re & Services
more
|
|
|
|
|
17.9
|
65679767212eaade2e0ee26f
|
2019
|
World Health Organisation
|
WHO Core Voluntary contributio...ns
more
|
2019002454
|
1.006
|
8
|
Sudan
|
South of Sahara
|
LDCs
|
ODA Grants
|
4
|
10
|
110
|
C01
|
0.00836287
|
0.00836287
|
0
|
0
|
0.00836287
|
0.00836287
|
|
|
|
|
Communicable diseases
|
Communicable diseases Other
|
100
|
CVCA_278_1.6 ANTIMICROBIAL RES...ISTANCE
more
|
CVCA_278_1.6 Antimicrobial res...istance
more
|
Antimicrobial resistance
|
0
|
12220
|
Basic health care
|
3.3
|
I.2.b. Basic Health
|
41143
|
World Health Organisation - co...re voluntary contributions account
more
|
WHO-CVCA
|
|
3.3
|
65679769212eaade2e0ee270
|
2019
|
United Kingdom
|
Department for Business, Energ...y and Industrial Strategy
more
|
2019003770
|
MRC_THA_MR/R018391/1
|
1
|
Thailand
|
Far East Asia
|
UMICs
|
ODA Grants
|
1
|
10
|
110
|
D02
|
0.130383
|
0.130383
|
0
|
0
|
0.130383
|
0.130383
|
0
|
0.130383
|
0
|
0
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
A PILOT ASSESSMENT OF MILTEFOS...INE'S EFFICACY AND TOLERABILITY FOR TREATING CUTANEOUS LEISHMANIA TROPICA IN AFGHANISTAN
more
|
A pilot assessment of miltefos...ine's efficacy and tolerability for treating cutaneous Leishmania tropica in Afghanistan
more
|
A pilot assessment of miltefos...ine's efficacy and tolerability for treating cutaneous Leishmania tropica in Afghanistan
more
|
NTDs
|
12182
|
Medical research
|
|
I.2.a. Health, General
|
11000
|
Donor Government
|
Donor Government
|
|
|
65679769212eaade2e0ee271
|
2019
|
United Kingdom
|
Department for Business, Energ...y and Industrial Strategy
more
|
2019003158
|
NF_MRC_THA_2.12
|
3
|
Thailand
|
Far East Asia
|
UMICs
|
ODA Grants
|
1
|
10
|
110
|
D02
|
0.683217
|
0.683217
|
0
|
0
|
0.683217
|
0.683217
|
0
|
0.683217
|
0
|
0
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
MRC THAI NATIONAL SCIENCE AND ...TECHNOLOGY DEVELOPMENT AGENCY (NSTDA) JOINT CALL; DISEASES OF RELEVANCE TO THAILAND
more
|
MRC Thai National Science and ...Technology Development Agency (NSTDA) joint call; Diseases of relevance to Thailand
more
|
Collaborative research program...me between the UK and Thailand to support bilateral research projects focused on addressing infectious diseases of relevance to Thailand. In particular AMR, emerging infectious diseases, measles and mosquito borne diseases.
more
|
|
12182
|
Medical research
|
|
I.2.a. Health, General
|
11000
|
Donor Government
|
Donor Government
|
|
|
6567976a212eaade2e0ee272
|
2020
|
Switzerland
|
Cantons and municipalities
|
2019003875
|
030-Q32-2019-336
|
3
|
Western Africa, regional
|
South of Sahara
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0.005325
|
0.005325
|
0
|
0
|
0.005325
|
0.005325
|
|
0.005325
|
|
|
Classified as not health-speci...fic activity
more
|
|
100
|
MÉTISSAGES
|
Métissages
|
Decentralised Development Coop...eration
more
|
0
|
12230
|
Basic health infrastructure
|
6,3
|
I.2.b. Basic Health
|
22000
|
Donor country-based NGO
|
|
|
|
6567976a212eaade2e0ee273
|
2020
|
United Kingdom
|
Department for Business, Innov...ation and Skills
more
|
2020006975
|
GCRF_MRC_AA_MR/S019170/1
|
3
|
Africa, regional
|
Africa
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
D02
|
0
|
1.207648
|
0
|
0
|
0
|
1.207648
|
0
|
0
|
0
|
0
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
MICA: DEVELOPMENT OF NEW AGENT...S FOR THE TREATMENT OF CRYPTOSPORIDIOSIS
more
|
MICA: Development of new agent...s for the treatment of cryptosporidiosis
more
|
A recent clinical study in Afr...ica and South Asia has found that cryptosporidiosis is one of the most significant causes of death and illness from diarrheal diseases amongst children in the developing world. Cryptosporidiosis is caused by a single-celled protozoan parasite, the predominant species infecting humans are called Cryptosporidium hominis and Cryptosporidium parvum. This parasite mainly lives in the cells in the gut wall and has a complex life-cycle. Infection occurs due to consumption of water or food contaminated with the parasites. Parasites are spread from an infected individual through their faeces. In people who are healthy and well nourished, the disease clears naturally within a couple of weeks. However, in people who are malnourished (particularly in young children) and people with an immune system that is not functioning properly (for example HIV/AIDS victims), the disease can have a much more significant impact. It is the major contributor to life-threatening diarrhea in young children, with 2.9-4.7 million cases in children under 24 months in sub-Saharan Africa and the Indian sub-continent, leading to more than 200,000 deaths per year. Cryptosporidiosis is also associated with malnutrition and stunted growth in children and probably causes chronic infections, which last for weeks or months. The only drug registered for the treatment of this disease is nitazoxanide, which is not very effective, especially in those patients who are most severely affected due to a weak immune system and/ or malnutrition. Therefore there is an urgent need for the development of new drugs to treat: (1) children <24 months, especially those that are malnourished and with chronic diarrhea, and (2) immunocompromised children and adults with advanced AIDS and chronic diarrhea. Cryptosporidium may be the cause of as much as 75% of chronic diarrhea in this patient cohort. We have discovered some chemical starting points that can be used for a drug discovery programme. We have a series of compounds that kill the parasites and also are very effective in clearing the parasites from rodent models of cryptosporidiosis. The compounds are thought to work through preventing the parasite making proteins. The aim of this project is to take these starting points and optimise them to make a molecule which has the potential to be a drug. This will require us to optimise multiple features of the molecule: its ability to kill the parasite, its ability to reach the sites in the body where the parasite resides without being broken down, and its safety. At the end of this project we hope to have a 'preclinical candidate'. This is a compound that we think should be suitable to enter human clinical trials. The steps after this project, prior to human clinical trials will be to make the compound on a larger scale under properly defined conditions and to carry out formal safety testing.
more
|
0
|
12182
|
Medical research
|
|
|
11000
|
Donor Government
|
Donor Government
|
|
|
6567976a212eaade2e0ee274
|
2020
|
United Kingdom
|
Department for Business, Innov...ation and Skills
more
|
2020006971
|
GCRF_MRC_AA_MR/T004045/1
|
3
|
Africa, regional
|
Africa
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
D02
|
0
|
0.088094
|
0
|
0
|
0
|
0.088094
|
0
|
0
|
0
|
0
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
PREPARATION FOR THE RANDOMISED... EVALUATION OF A VITAMIN C BUNDLE FOR SEPSIS TREATMENT IN AFRICA (REVISTA-PREP)
more
|
Preparation for the Randomised... Evaluation of a VItamin C bundle for Sepsis Treatment in Africa (REVISTA-Prep)
more
|
Preparation for Randomised Eva...luation of a VItamin C bundle for Sepsis Treatment in Africa (REVISTA-Prep) Key points: 1) Sepsis is a life-threatening infection that can result in failure of vital organs, it is responsible for more than 7 million deaths annually, a large percentage of which occur in Africa. 2) Emerging research shows promising benefits in patients with sepsis treated with 'metabolic resuscitation' using combinations of hydrocortisone (steroids), intravenous vitamin C (ascorbic acid) and intravenous vitamin B1 (thiamine). 3) Different studies are underway in the US, Europe, Asia, and South America to understand whether combinations of these medicines or the medicines individually can help improve the chances of someone with sepsis. Although none of these studies are being conducted in Africa, the different medicines that are included in this treatment are inexpensive, readily available and relatively safe to administer. 4) It is critical that similar studies are conducted in Africa to evaluate whether or not providing any of these medicine or a combination of them can help save people there from dying of sepsis. 5) If the studies prove that these medicines can improve survival from sepsis, there is a large potential to save many lives because each of the medicines are inexpensive, readily available and relatively safe to administer. Through this Joint Global Health Trials Development Award, we intend to conduct preliminary research in Uganda (East Africa) to help us understand better what we might need to consider for conducting a future large trial that studies which of the combinations of vitamin C, vitamin B1, and steroids (or the medicines individually) will be best at improving survival from sepsis in African settings, where the resources are constrained, intensive care units are rare, and issues like poverty, malnutrition, and HIV are common. Specifically, we will conduct a series of small studies to understand how common deficiencies of vitamin C and B1 are in sepsis patients who are HIV-infected compared to healthy individuals with and without HIV. We will also investigate or not there is a link between having low levels of these vitamins and death in sepsis patients. In addition, we will provide varying doses of vitamin C (alongside vitamin B1) to another small group of sepsis patients so we can gain a better understanding of the correct dose we should use in the future trial and whether there are any laboratory tests or clinical signs we can use to monitor the vitamin C levels specifically. Finally, because we will be conducting the future trial in a population of patients who are severely ill, we would like to interview clinicians, patients, and people living in the community about their understanding of what it means to be enrolled in a large clinical trial for which it is unclear whether the medicine being studied can help you and where you will not be able to decide which of the different medicines you will ul
more
|
0
|
12182
|
Medical research
|
|
|
11000
|
Donor Government
|
Donor Government
|
|
|
6567976a212eaade2e0ee275
|
2020
|
United Kingdom
|
Department for Business, Innov...ation and Skills
more
|
2020006974
|
GCRF_MRC_NS_MR/R005958/1
|
3
|
Africa, regional
|
Africa
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
D02
|
0
|
0.632555
|
0
|
0
|
0
|
0.632555
|
0
|
0
|
0
|
0
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
INTERNATIONAL VETERINARY VACCI...NOLOGY NETWORK
more
|
International Veterinary Vacci...nology Network
more
|
In many 'low-middle-income-cou...ntries' (LMICs) the livestock sector (including poultry and aquaculture) accounts for up to 80% of agricultural GDP, with a majority of the rural poor raising livestock as a means of securing or diversifying income. Improving livestock productivity through the development and deployment of effective veterinary vaccines is thus critical not only to secure food supply and contain the many zoonotic (i.e. transmissible from animal to human) diseases that are prevalent in LMICs, but also to secure income and thus offer a pathway for alleviating poverty. Despite several successful multi-national collaborations addressing livestock health in LMICs there is still not a 'universal' Network that can be readily accessed by all researchers working on veterinary vaccine development for LMIC-application. There is also a continuing unmet demand for increased knowledge and technology transfer between researchers in the UK and LMICs and also between researchers in the human and veterinary vaccinology communities. Here we propose the formation of an International Veterinary Vaccinology Network (IVVN) that provides a forum for the integration of inputs from biological scientists, other specialists (e.g. economists), industry, policymakers and regulatory bodies to focus specifically on development of vaccines for priority livestock diseases of LMICs. By establishing an integrated community and facilitating the formation of strategically devised collaborations between scientists with complementary expertise, the IVVN will enable new approaches to tackling the many scientific 'bottle-necks' that frustrate vaccine development to be adopted. As many of the scientific obstacles that impede development of vaccines are common to both human and veterinary vaccinology, the research conducted by IVVN members will frequently have implications for human vaccine development and so fulfil a 'one-health' remit. The IVVN will actively seek to engage scientists and industrial partners (including those who may not usually consider applying their skills to LMIC or veterinary problems) from the breadth of disciplines that can be applied to vaccine development. The IVVN will provide opportunities for new inter-disciplinary partnerships that tackle specific scientific challenges to be formed (member-led annual scientific meetings and workshops) and then support these partnerships by funding preliminary experiments to generate novel scientific findings (pump-priming funding and laboratory exchanges) that will contribute to the development of new vaccines. The IVVN will identify opportunities across the whole spectrum of veterinary vaccinology where application of new scientific approaches can effectively address long-standing obstacles to vaccine design, to keep abreast of these opportunities the IVVN has assembled a management board that has a wide profile of veterinary and human vaccinology expertise that will enable rapid integration of new scientific d
more
|
0
|
12182
|
Medical research
|
|
|
11000
|
Donor Government
|
Donor Government
|
|
|
6567976a212eaade2e0ee276
|
2020
|
United Kingdom
|
Department for Business, Innov...ation and Skills
more
|
2020006973
|
GCRF_MRC_AR_MR/T016124/1
|
3
|
Africa, regional
|
Africa
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
D02
|
0
|
0.101828
|
0
|
0
|
0
|
0.101828
|
0
|
0
|
0
|
0
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
EVALUATING MULTIPLE LOCI MODUL...ATING SUSCEPTIBILITY OF AFRICAN MALARIA PARASITES TO ARTEMISININ
more
|
Evaluating multiple loci modul...ating susceptibility of African malaria parasites to artemisinin
more
|
Combination drugs for treatmen...t of malaria deployed globally since the start of the 21st century have provided a substantial public health benefit. Malaria deaths across Africa in particular have plummeted since a peak in the 1990s, when failure of the drugs chloroquine and sulphadoxine-pyrimethamine precipitated a rise in infant and child deaths. A key component in all the currently effective drug combinations is the plant-derived chemical called artemisinin. The parasite-killing ability of artemisinin has recently been threatened by the emergence of reduced susceptibility in the Mekong region: this is manifest as a slowing of artemisinin clearance of P. falciparum from the blood of treated malaria patients. Although under combination treatments these patients should eventually experience a full cure in most cases, in this region the combination partner drugs are also failing in some patients. Careful monitoring and vigilance of malaria drug resistance is therefore needed. A parasite gene has been identified in Cambodia and the surrounding region which contributes to the loss of effectiveness of the artemisinin drug - this gene, which encodes a kelch-domain protein and is called K13, has accumulated a variety of mutations. These are strongly associated with the loss of effectiveness of artemisinin against these parasites. However, this same phenomenon has not yet been observed in African malaria parasites - in the small number of cases where drug treatment does not work, K13 mutations are not implicated as the cause. In the past 2 years, gene-editing studies by ourselves and others have successfully demonstrated a direct effect of 3 genes in reducing susceptibility to artemisinin : pfap2mu, pfubp1 and pfcoronin. Variants of these genes elicit increased parasite survival in vitro in the ring-stage artemisinin survival assay (RSA). In the case of trafficking adaptor potein subunit AP-2mu, we have shown that the role of this protein in P. falciparum is unlike in other organisms as it does not interact with clathrin, but is associated with an as yet unknown compartment in the cell that appears to also contain K13, although we found no evidence of direct interaction between AP-2mu and the K13 protein. There is, however, good evidence of direct interaction of AP-2mu with a different kelch protein , K10. Polymorphisms in the gene encoding the K10 protein have been previously identified as a genetic component of parasites from the Mekong region in which the K13-dependent reduced artemisinin susceptibility originally arose. This work was carried out by PhD student Ryan Henrici, who completed his doctoral studies in 2018 and has moved on. We now request support to extend this work, using gene editing to test the effect of new mutations. In preliminary studies of both field samples and UK isolates, we have already identified a number of such new mutations in our current five genes of interest - pfk13, pfap2mu, pfubp1, pfcoronin and pfk10 (see Case f
more
|
|
12182
|
Medical research
|
|
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
University, college or other t...eaching institution, research institute or think?tank
more
|
|
|
6567976a212eaade2e0ee277
|
2020
|
United Kingdom
|
Department for Business, Innov...ation and Skills
more
|
2020007488
|
GCRF-RSRFFLAIR-FR12020-FLR\R1\...201390
more
|
3
|
Africa, regional
|
Africa
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
D02
|
0
|
0.164615
|
0
|
0
|
0
|
0.164615
|
0
|
0
|
0
|
0
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
NEW ORGANOMETALLIC ANTIPLASMOD...IAL AGENTS: INVESTIGATION OF THEIR TOXICITY, CYTOTOXICITY AND POTENTIAL PARASITIC TARGETS
more
|
New Organometallic Antiplasmod...ial Agents: Investigation of their toxicity, cytotoxicity and potential parasitic targets
more
|
Fellowship award based in Sout...h Africa. Preparing new metallodrugs that can combat drug-resistant malaria, and investigating their toxicity, cytotoxicity and potential parasitic targets. SDG 3.
more
|
|
12262
|
Malaria control
|
|
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
University, college or other t...eaching institution, research institute or think?tank
more
|
|
|
6567976b212eaade2e0ee278
|
2020
|
United Kingdom
|
Department of Health and Soci...al Care
more
|
2020009739
|
RP_2017_08_ST2_012
|
3
|
Botswana
|
South of Sahara
|
UMICs
|
ODA Grants
|
1
|
10
|
110
|
D02
|
0
|
0.437713
|
0
|
0
|
0
|
0.437713
|
0
|
|
|
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
NIHR GLOBAL RESEARCH PROFESSOR...SHIPS: TRANSLATIONAL RESEARCH TO REDUCE MORTALITY FROM CENTRAL NERVOUS SYSTEM (CNS) INFECTIONS IN AFRICA
more
|
NIHR Global Research Professor...ships: Translational Research to Reduce Mortality from Central Nervous System (CNS) Infections in Africa
more
|
The NIHR Global Research Profe...ssorship scheme is open to all professions and all Higher Education Institutions (HEI), based in England and the Devolved Administrations, to nominate health researchers and methodologists with an outstanding research record of clinical and applied health research and its effective translation for improved health. Global Research Professors are required to have existing strong collaborations or links with collaborators or partners in institutions in countries on the OECD DAC list and the award should plan to strengthen these/support training and capacity development/mentorship in these partners. Infections of the central nervous system (CNS) are major causes of mortality in low- and middle-income countries. This research aims to generate a detailed understanding of the aetiology of adult meningitis in this setting to inform diagnostic pathways and treatment strategies. The research group will evaluate affordable point-of-care diagnostic tests for meningitis, which are urgently needed to facilitate diagnosis, screening and prevention strategies, and trial novel effective treatments required to improve patient outcomes. The project is based in Botswana and the majority of the research will be conducted in this region.
more
|
|
12182
|
Medical research
|
|
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
University, college or other t...eaching institution, research institute or think?tank
more
|
|
|
6567976b212eaade2e0ee279
|
2020
|
United Kingdom
|
Department for Business, Innov...ation and Skills
more
|
2020006987
|
GCRF_MRC_BRA_MR/S002340/1
|
3
|
Brazil
|
South America
|
UMICs
|
ODA Grants
|
1
|
10
|
110
|
D02
|
0
|
0.242415
|
0
|
0
|
0
|
0.242415
|
0
|
0
|
0
|
0
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
MRC-FAPESP: NEW APPROACHES TO ...THE TREATMENT OF PARACOCCIDIOIDOMYCOSIS
more
|
MRC-FAPESP: New approaches to ...the treatment of Paracoccidioidomycosis
more
|
Humans have evolved complex an...d effective ways of fighting infections caused by microbes such as bacteria, parasites, fungi and viruses, the immune system. Sometimes the immune system goes wrong and this can cause serious diseases such as rheumatoid arthritis and diabetes. Our research aims to understand at a molecular level how the cells of the immune system are able to recognise different microbes and the ways in which these cells respond to cause the familiar symptoms of an infection such as fever and tiredness, and to generate specific antibodies that fight the invading microbes. In this project we will study the way in which immune system cells are activated by sugar-binding proteins associated pathogenic yeasts and plants, in particular the way they bind and activate the Toll-like receptors of the innate immune system. Understanding the molecular basis for interactions between these pathogens and immune cells will allow us to carry out a screen to identify new candidate drugs that might be effective therapies for these important diseases.
more
|
0
|
12182
|
Medical research
|
|
|
11000
|
Donor Government
|
Donor Government
|
|
|
6567976c212eaade2e0ee27a
|
2020
|
United Kingdom
|
Department for Business, Innov...ation and Skills
more
|
2020008059
|
NF_MRC_BRA_2.01
|
3
|
Brazil
|
South America
|
UMICs
|
ODA Grants
|
1
|
10
|
110
|
D02
|
0
|
0.998225
|
0.001168
|
0
|
0
|
0.998225
|
0.001168
|
0
|
0
|
0
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
A UK-BRAZIL JOINT CENTRE PARTN...ERSHIP CALL TO SUPPORT THREE JOINT CENTRES TO DELIVER COLLABORATIVE RESEARCH PROGRAMMES AND CAPACITY BUILDING ACTIVITIES
more
|
A UK-Brazil Joint Centre Partn...ership Call to support three joint centres to deliver collaborative research programmes and capacity building activities
more
|
A UK-Brazil Joint Centre Partn...ership Call to support three joint centres to deliver collaborative research programmes and capacity building activities in the area of neglected infectious diseases of importance to Brazil. The call will focus on diseases impacting the most vulnerable in society, including zika, dengue, chikungunya, schistosomiasis and leprosy.
more
|
NTD
|
12182
|
Medical research
|
|
|
11000
|
Donor Government
|
Donor Government
|
|
|
6567976c212eaade2e0ee27b
|
2020
|
United Kingdom
|
Department for Business, Innov...ation and Skills
more
|
2020007497
|
GCRF-CICA-R12016-IC160044
|
3
|
Brazil
|
South America
|
UMICs
|
ODA Grants
|
1
|
10
|
110
|
D02
|
0
|
0.094908
|
0
|
0
|
0
|
0.094908
|
0
|
0
|
0
|
0
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
DESIGNING AND DELIVERY NEW ANT...ILEISHMANIALS
more
|
Designing and Delivery New Ant...ileishmanials
more
|
Research Grant - Collaboration... between UK and Brazil. Designing new drugs for the treatment of leishmaniasis, a neglected tropical disease affecting many developing countries. This project focuses on developing new oral and topical treatments of leishmaniases within Brazil. SDG 3.
more
|
NTD - leishmaniasis
|
12250
|
Infectious disease control
|
|
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
University, college or other t...eaching institution, research institute or think?tank
more
|
|
|
6567976c212eaade2e0ee27c
|
2020
|
United Kingdom
|
Department for Business, Innov...ation and Skills
more
|
2020008386
|
MRC_BFA_MR/P02016X/1
|
3
|
Burkina Faso
|
South of Sahara
|
LDCs
|
ODA Grants
|
1
|
10
|
110
|
D02
|
0
|
0.170744
|
0
|
0
|
0
|
0.170744
|
0
|
0
|
0
|
0
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
INVESTIGATING THE HUMAN MALARI...A RESERVOIR OF TRANSMISSION DURING PREGNANCY
more
|
Investigating the Human Malari...a Reservoir of Transmission during Pregnancy
more
|
MRC African Res Leaders Sep 20...16 award - Investigating the Human Malaria Reservoir of Transmission during Pregnancy
more
|
0
|
12182
|
Medical research
|
|
|
11000
|
Donor Government
|
Donor Government
|
|
|
6567976c212eaade2e0ee27d
|
2020
|
United Kingdom
|
Department for Business, Innov...ation and Skills
more
|
2020006988
|
GCRF_MRC_AA_MR/P025501/1
|
3
|
Burkina Faso
|
South of Sahara
|
LDCs
|
ODA Grants
|
1
|
10
|
110
|
D02
|
0
|
0.07997
|
0
|
0
|
0
|
0.07997
|
0
|
0
|
0
|
0
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
DEVELOPMENT OF A NEW TOOL FOR ...MALARIA MOSQUITO SURVEILLANCE TO IMPROVE VECTOR CONTROL
more
|
Development of a new tool for ...malaria mosquito surveillance to improve vector control
more
|
Since the year 2000, controlli...ng mosquitoes with insecticide-based interventions has led to a 37% reduction in malaria mortality globally. Nevertheless, malaria still caused 438 000 deaths in 2015, and further progress is being threatened by increasing levels of insecticide resistance in mosquito vectors. The global malaria community urgently needs new tools to monitor mosquito vector populations. Several aspects of mosquito demography and physiology are particularly crucial for planning and assessing vector control strategies. Prime amongst these are determination of mosquito vector species and age structure. Accurate species identification is required to confirm what vectors are responsible for transmission. Mosquito age is a critical determinant of their transmission potential. This is because the malaria parasite undergo a period of development within the vector before they become transmissible. Additionally, measurement of insecticide resistance status is essential to assess how effectively vectors could be targeted by current frontline control methods such as Insecticide Treated Nets (ITNs) and spraying. Unfortunately, no methods are currently available for rapid, large-scale and simultaneous measurement of these crucial mosquito vector demographic and physiological traits. This proposal aims to fill that gap by developing and validating a novel technology for high throughput, high precision surveillance of malaria vector populations in LMICs. This project aims to develop such a tool for malaria vectors on the basis on strong existing partnerships with leading African malaria researchers, and world-class physical chemists and vector biologists in the UK. Specifically, the technology is based on the measurement of molecular signature of the mosquito cuticle, which is the outer part of the insects, to predict key traits (species, age and insecticide resistance). Indeed, the composition and structure of the mosquito cuticle, similar to the mammalian skin, changes when the organism ages, it is different in different species, and it is altered in mosquitoes that are resistant to insecticides. Here, we propose to characterize the cuticular changes associated with the traits mentioned above to then make predictions on individual mosquitoes of unknown conditions. The proposed technology is rapid and cost effective as it is based on the measurement of the light absorbed by mosquitoes, a procedure that do not require any sample preparation nor chemical reagents, and it is readily performed in few seconds by a spectrophotometer. The spectra - corresponding to the light absorbed by individual mosquitoes - will be analysed by powerful computational analysis which will enable to estimate the mosquito traits. We will follow a two-stage process starting with laboratory evaluation of mosquitoes at the University of Glasgow to build on our compelling pilot work on the use of Mid Infrared Spectroscopy (MIRS) coupled with artificial neural network (
more
|
|
12182
|
Medical research
|
|
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
University, college or other t...eaching institution, research institute or think?tank
more
|
|
|
6567976c212eaade2e0ee27e
|
2020
|
United Kingdom
|
Department for Business, Innov...ation and Skills
more
|
2020008387
|
MRC_KHM_MR/R003467/1
|
3
|
Cambodia
|
Far East Asia
|
LDCs
|
ODA Grants
|
1
|
10
|
110
|
D02
|
0
|
0.016769
|
0
|
0
|
0
|
0.016769
|
0
|
0
|
0
|
0
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
COMBATING DRUG RESISTANCE THRO...UGH BETTER GOVERNANCE OF UNREGULATED ANTIMICROBIAL SELLERS IN CAMBODIA: ADDRESSING STAKEHOLDER CONNECTIONS & PERCEPTIONS
more
|
Combating drug resistance thro...ugh better governance of unregulated antimicrobial sellers in Cambodia: addressing stakeholder connections & perceptions
more
|
MRC JHSRI Foundation 2017 awar...d - Combating drug resistance through better governance of unregulated antimicrobial sellers in Cambodia: addressing stakeholder connections & perceptions
more
|
0
|
12182
|
Medical research
|
|
|
11000
|
Donor Government
|
Donor Government
|
|
|
6567976c212eaade2e0ee27f
|
2020
|
United Kingdom
|
Department for Business, Innov...ation and Skills
more
|
2020008388
|
MRC_AA_MR/R010099/1
|
3
|
Cameroon
|
South of Sahara
|
LMICs
|
ODA Grants
|
1
|
10
|
110
|
D02
|
0
|
0.275051
|
0
|
0
|
0
|
0.275051
|
0
|
0
|
0
|
0
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
TARGETING THE IL-33-INFLAMMASO...ME AXIS IN THERAPY FOR CEREBRAL MALARIA
more
|
Targeting the IL-33-inflammaso...me axis in therapy for cerebral malaria
more
|
MRC IIB award - Targeting the ...IL33inflammasome axis in therapy for cerebral malaria
more
|
0
|
12182
|
Medical research
|
|
|
11000
|
Donor Government
|
Donor Government
|
|
|
6567976d212eaade2e0ee280
|
2020
|
United Kingdom
|
Department for Business, Innov...ation and Skills
more
|
2020007502
|
GCRF-RSRFFLAIR-FR12020-FLR\R1\...201216
more
|
3
|
Cameroon
|
South of Sahara
|
LMICs
|
ODA Grants
|
1
|
10
|
110
|
D02
|
0
|
0.14637
|
0
|
0
|
0
|
0.14637
|
0
|
0
|
0
|
0
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
MONITORING THE ESTABLISHMENT O...F RESISTANCE IN CLOTHIANIDIN-SELECTED POPULATIONS OF ANOPHELES GAMBIAE
more
|
Monitoring the establishment o...f resistance in clothianidin-selected populations of Anopheles gambiae
more
|
Fellowship award based in Came...roon. Evaluating the speed at which mosquito species that carry malaria in Africa can become resistant to a new insecticide, informing future malaria control programs. SDG 3.
more
|
|
12262
|
Malaria control
|
|
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
University, college or other t...eaching institution, research institute or think?tank
more
|
|
|
6567976d212eaade2e0ee281
|
2020
|
United Kingdom
|
Department for Business, Innov...ation and Skills
more
|
2020006739
|
GCRF_EPSRC_AA_EP/R013969/1
|
3
|
Cameroon
|
South of Sahara
|
LMICs
|
ODA Grants
|
1
|
10
|
110
|
D02
|
0
|
0.123959
|
0
|
0
|
0
|
0.123959
|
0
|
0
|
0
|
0
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
DETAILED MALARIA DIAGNOSTICS W...ITH INTELLIGENT MICROSCOPY
more
|
Detailed malaria diagnostics w...ith intelligent microscopy
more
|
The best way to diagnose malar...ia remains microscopic examination of blood smears, to identify the plasmodium parasites that are responsible. This takes around 30 minutes of microscopy, done by a trained technician - skilled workers who are in short supply. This project will create an intelligent microscope that can greatly multiply the skills of a technician by scanning over the smears automatically, and allowing them to review only the suspicious blood cells on a tablet computer after the smear has been scanned. Malaria is one of the world's most prevalent infectious diseases. It affects 200 million per year, and causes around 400 thousand deaths - most of them children in ODA countries in sub-Saharan Africa. Impressive progress is being made in reducing the incidence of malaria, which makes good diagnosis of the condition ever more important, it is increasingly inaccurate to assume that every patient with a fever has malaria, and doing so will waste drugs and leave potentially life threatening fevers untreated. The key to reliable, useful diagnosis with an automated microscope lies in computer vision, simply acquiring digital images and tiling them together into a digital smear is an important first step, but robust analysis of the digital images means the technician need not sift through many images of healthy cells. Instead, they can concentrate their efforts on parts of the image where the algorithm identified suspicious features. Once trained, our algorithm will be able to identify many parasites, only asking for the technician's opinion in challenging, ambiguous cases when it could not identify objects with certainty. Fully automated counts of healthy and infected cells will then allow consistent quantification of test results, informing the clinician prescribing treatment and aiding in disease monitoring. Analysis of medical images raises fundamental issues with the standard 'deep learning' approach of training a multi-layer neural network on hundreds of thousands of images. Such algorithms cannot accurately quantify their uncertainty (i.e. flag up when a diagnosis may be inaccurate), nor describe the reasoning that led to a given classification for an image. They require extremely large training datasets, which must often be labelled by hand. We will build a generative probabilistic model which, while not feasible in most applications due to the huge range of objects that might conceivably be found in a photograph, is possible in the relatively controlled imaging environment of a microscope. This will allow us to give a probabilistic verdict on each cell, and highlight cells that couldn't be reliably classified as healthy, infected, or something else. The generative model will also be able to identify features that led to a classification, for example highlighting infected cells in a large image of a smear. Both of these features will enable greater trust in the algorithm, and allow it to be used to support, rather tha
more
|
Malaria
|
43082
|
Research/scientific institutio...ns
more
|
|
|
11000
|
Donor Government
|
Donor Government
|
|
|
6567976d212eaade2e0ee282
|
2020
|
United Kingdom
|
Department for Business, Innov...ation and Skills
more
|
2020006991
|
GCRF_MRC_CN_MR/T003995/1
|
3
|
China (People's Republic of)
|
Far East Asia
|
UMICs
|
ODA Grants
|
1
|
10
|
110
|
D02
|
0
|
0.12718
|
0
|
0
|
0
|
0.12718
|
0
|
0
|
0
|
0
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
SCHOOL-BASED EDUCATION PROGRAM...ME TO REDUCE SALT: SCALING-UP IN CHINA (EDUSALTS)
more
|
School-based education program...me to reduce salt: Scaling-up in China (EduSaltS)
more
|
High salt intake increases the... risk of high blood pressure, strokes, heart disease, and several other chronic diseases such as stomach cancer. Salt intake in China is very high with an average of 12-14 gram per day, more than double the WHO recommended level of 5 gram per day. Unlike the UK and other developed countries, 75%-80% of the salt in the Chinese diet is added by the consumers during cooking or in sauces. An effective strategy to reduce salt from home cooking is of great urgency and importance, not only for China, but also for many other developing countries. However, it is very difficult for individuals to change their eating habits. Our proposed research will build upon a successfully-tested pilot study entitled 'School-based education programme to reduce Salt' (School-EduSalt) in China, in which primary school children were educated, during their usual health education lessons, about the effects of salt on health and how to reduce salt intake. Children then instructed their family members to reduce the amount of salt used during food preparations at home. The results of this pilot study have shown that the school-based education is very effective in reducing salt intake in children and adults. The pilot study was carried out in one city called Changzhi, in northern China. We now propose to do a study to test whether we can scale up a refined School-EduSalt programme in multiple settings, to reduce salt in larger populations in China, including the poorest population living in the remote and rural areas. This scale-up study will be carried out in three regions of China including Beijing (capital of China), Shijiazhuang (in the north) and Zhenjiang (in the south), covering a population of over 1 million school children and 2.2 million adults. The study will involve a number of important stakeholders, including governmental organisations, and the health and education authorities of the three regions. Based on WHO's Conceptual Framework for Scaling up, we will work with these stakeholders to develop, implement and evaluate a feasible scale-up package, which will be integrated into the existing school health education system to ensure sustainable scaling-up. The scale-up package will be evaluated in three aspects: effectiveness, process and health economics. We will assess whether the education programme can improve the participants' knowledge, attitudes and practices towards salt reduction. Additionally, we will assess whether the education programme can achieve a sustainable reduction in salt intake which will be measured by the gold standard method of 24-hour urine collection. Our ultimate aim is to incorporate the refined education programme into the national school curriculum, so that all schools in China will follow. A nation-wide implementation will have an enormous impact on reducing population salt intake. A reduction in salt intake across the whole population, even by a small amount, will lower population blood pressure and pr
more
|
0
|
12182
|
Medical research
|
|
|
11000
|
Donor Government
|
Donor Government
|
|
|
6567976d212eaade2e0ee283
|
2020
|
United Kingdom
|
Department for Business, Innov...ation and Skills
more
|
2020008060
|
NF_MRC_CHN_76
|
3
|
China (People's Republic of)
|
Far East Asia
|
UMICs
|
ODA Grants
|
1
|
10
|
110
|
D02
|
0
|
0.115245
|
0
|
0
|
0
|
0.115245
|
0
|
0
|
0
|
0
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
I) TO SUPPORT HIGH QUALITY UK-...CHINESE RESEARCH COLLABORATIONS IN THE AREA OF ANTIMICROBIAL RESISTANCE, LEADING TO SCIENTIFIC OUTPUTS OF RELEVANCE TO C
more
|
i) To support high quality UK-...Chinese research collaborations in the area of antimicrobial resistance, leading to scientific outputs of relevance to C
more
|
MRC-BBSRC-ESRC-NSFC Joint Rese...arch Funding Call in Antimicrobial Resistance, focusing on issues of importance to China. AMR is a significant issue worldwide but particularly for developing countries, where often the issue is exasperated by widespread inappropriate use of antimicrobials. AMR poses a serious public health threat to the Chinese population.
more
|
0
|
12182
|
Medical research
|
|
|
11000
|
Donor Government
|
Donor Government
|
|
|
6567976d212eaade2e0ee284
|
2020
|
United Kingdom
|
Department for Business, Innov...ation and Skills
more
|
2020007509
|
GCRF-CICA-R12016-IC160063
|
3
|
China (People's Republic of)
|
Far East Asia
|
UMICs
|
ODA Grants
|
1
|
10
|
110
|
D02
|
0
|
0.096191
|
0
|
0
|
0
|
0.096191
|
0
|
0
|
0
|
0
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
SUSTAINABLE PRODUCTION AND DIV...ERSIFICATION OF NATURAL PRODUCTS TO COMBAT DISEASES IN THE DEVELOPING WORLD
more
|
Sustainable Production and Div...ersification of Natural Products to Combat Diseases in the Developing World
more
|
Research Grant - Collaboration... between UK and China. Developing technologies to enable low-income countries to establish sustainable and low cost manufacture of natural products, which are used to treat and prevent transmission of diseases in the developing world. SDGs 3,9,12.
more
|
|
31182
|
Agricultural research
|
|
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
University, college or other t...eaching institution, research institute or think?tank
more
|
|
|
6567976d212eaade2e0ee285
|
2020
|
United Kingdom
|
Department for Business, Innov...ation and Skills
more
|
2020006422
|
GCRF-RFNetG-R6-GCRFNGR6\1548
|
3
|
Democratic Republic of the Con...go
more
|
South of Sahara
|
LDCs
|
ODA Grants
|
1
|
10
|
110
|
D02
|
0
|
0.03156
|
0
|
0
|
0
|
0.03156
|
0
|
0
|
0
|
0
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
HOUSE-BASED INTERVENTIONS FOR ...MALARIA CONTROL IN THE DEMOCRATIC REPUBLIC OF THE CONGO
more
|
House-based interventions for ...malaria control in The Democratic Republic of the Congo
more
|
Malaria is a major burden on t...he Democratic Republic of the Congo (DRC), and particularly affects the poorest of the poor. The burden of disease is extremely high in the country, comprising 12% of the global cases of malaria (World Malaria Report, 2019). About 80% of the population in DRC live on less than $1 a day, with diseases like malaria reducing the economic resilience of the poor. At present, the major malaria intervention is insecticide-treated bednets, but malaria cases have not declined in recent years despite massive deployment of nets, underlying the need to develop additional interventions against this disease. The DRC has many challenges to improve the control of malaria in the country, including its large size and weak infrastructure, its great ecological diversity, high rainfall, extreme poverty and insecurity, coupled with limited expertise to deploy interventions at scale. This project aims to find new tools and interventions that could be used to reduce malaria in rural DRC. In its 2020-2024 strategic plan, the National Malaria Control Programme (NMCP) demonstrates a clear need to strengthen vector control in the country. This has led us to propose bringing together a working group including entomologists and the malaria control specialists from Africa (DRC, Benin and Gambia) and members of the GCRF funded BOVA (Building Out Vector borne diseases in Africa) Network based at the University of Durham (UK) to explore house based options for malaria control including insecticide-treated eave ribbons, eaves tubes and screening.
more
|
|
43082
|
Research/scientific institutio...ns
more
|
|
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
University, college or other t...eaching institution, research institute or think?tank
more
|
|
|
6567976d212eaade2e0ee286
|
2020
|
United Kingdom
|
Department for International D...evelopment
more
|
2016001114a
|
204765-103
|
3
|
Developing countries, unspecif...ied
more
|
Regional and Unspecified
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0
|
6.412723
|
0
|
0
|
0
|
6.412723
|
0
|
0
|
|
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
RESEARCH ON DISEASE OUTBREAKS,... TO INFORM MORE EFFECTIVE PREPAREDNESS AND RESPONSE, IN PARTNERSHIP WITH WELLCOME
more
|
Research on Disease Outbreaks,... to inform more effective preparedness and response, in partnership with Wellcome
more
|
Epidemics and Global Health Se...curity Research Programme (Epidemics and GHS) - This programme will accelerate research and development for disease outbreaks (such as COVID19, Ebola etc) with the goal of preventing and tackling epidemics, saving lives and improving global health security. The programme will support the development of new vaccines, diagnostics and treatments for epidemic diseases and provide better evidence about outbreak diseases, to inform more effective preparedness and response activities.
more
|
0
|
12182
|
Medical research
|
|
|
21000
|
International NGO
|
INTERNATIONAL NGO
|
|
COVID-19
|
6567976e212eaade2e0ee287
|
2020
|
United Kingdom
|
Department for International D...evelopment
more
|
2017000335a
|
204765-104
|
3
|
Developing countries, unspecif...ied
more
|
Regional and Unspecified
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
B03
|
0
|
0.810834
|
0
|
0
|
0
|
0.810834
|
0
|
0
|
|
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
WHO (WORLD HEALTH ORGANISATION...) BLUEPRINT TO ACCELERATE RESEARCH & DEVELOPMENT FOR DISEASE OUTBREAKS
more
|
WHO (World Health Organisation...) Blueprint to Accelerate Research & Development for Disease Outbreaks
more
|
Epidemics and Global Health Se...curity Research Programme (Epidemics and GHS) - This programme will accelerate research and development for disease outbreaks (such as COVID19, Ebola etc) with the goal of preventing and tackling epidemics, saving lives and improving global health security. The programme will support the development of new vaccines, diagnostics and treatments for epidemic diseases and provide better evidence about outbreak diseases, to inform more effective preparedness and response activities.
more
|
0
|
12182
|
Medical research
|
|
|
41143
|
World Health Organisation - co...re voluntary contributions account
more
|
World Health Organisation - co...re voluntary contributions account
more
|
|
COVID-19
|
6567976e212eaade2e0ee288
|
2020
|
United Kingdom
|
Department for International D...evelopment
more
|
2017000718a
|
300342-101
|
3
|
Developing countries, unspecif...ied
more
|
Regional and Unspecified
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
D02
|
0
|
0.223086
|
0
|
0
|
0
|
0.223086
|
0
|
0
|
|
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
CAUSES OF FEVER STUDY: TO IDEN...TIFY THE PATHOGENS WHICH CAUSE FEVERS, TO TREAT THEM EARLY, TO IDENTIFY UNDERLYING LEVELS OF RESISTANCE TO EXISTING TREA
more
|
Causes of fever study: to iden...tify the pathogens which cause fevers, to treat them early, to identify underlying levels of resistance to existing trea
more
|
This programme in the Ross Fun...d Portfolio (which focusses on neglected tropical diseases, diseases of emerging resistance and diseases of epidemic potential) aims to build the evidence based on effective interventions and delivery mechanisms to tackle infectious diseases in low and middle income countries. The research programmes will take an integrated and multi-disciplinary approach to help DFID and the development community better understand what works most effectively to tackle infectious diseases, building upon the existing evidence base. The research addresses a number of core themes, including delivery through health systems, value for money of interventions, vulnerable groups, gender and building evidence on interventions in a range of contexts including (but not limited to) fragile and conflict affected states.
more
|
0
|
12182
|
Medical research
|
|
|
22000
|
Donor country-based NGO
|
Donor country-based NGO
|
|
COVID-19
|
6567976e212eaade2e0ee289
|
2020
|
United Kingdom
|
Department of Health and Soci...al Care
more
|
2020009778a
|
UKVN-CVD-IUK
|
3
|
Developing countries, unspecif...ied
more
|
Regional and Unspecified
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0
|
1.154141
|
0
|
0
|
0
|
1.154141
|
0
|
0
|
|
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
UK VACCINE NETWORK - CLINICAL ...VACCINE DEVELOPMENT COMPETITION
more
|
UK Vaccine Network - Clinical ...Vaccine Development Competition
more
|
This £35m competition support...s the development of new vaccines and vaccine technologies to combat diseases with epidemic potential in low and middle income countries (LMICs). It does this through supporting the clinical development of candidate vaccines and vaccine platform technologies which aim to tackle diseases of epidemic potential LMICs, ultimately to support an effective and rapid response during future outbreaks of disease in LMICs. This competition funds seven projects, which research a Chikungunya vaccine, an Ebola vaccine, a Zika Vaccine, a Nipah vaccine to eliminate porcine reservoirs and safeguard human health, a vaccine against mosquito borne diseases, a Zika and Chikungunya vaccine, and a Plague vaccine. This competition is run through Innovate UK.
more
|
0
|
12250
|
Infectious disease control
|
|
|
11001
|
Central Government
|
Central Government
|
|
COVID-19
|
6567976e212eaade2e0ee28a
|
2020
|
United Kingdom
|
Department of Health and Soci...al Care
more
|
2020009774a
|
UKVN-EFV-CCF
|
3
|
Developing countries, unspecif...ied
more
|
Regional and Unspecified
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0
|
0.038402
|
0
|
0
|
0
|
0.038402
|
0
|
0
|
|
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
UK VACCINE NETWORK - EPIDEMIOL...OGY FOR VACCINOLOGY COMPETITION
more
|
UK Vaccine Network - Epidemiol...ogy for Vaccinology Competition
more
|
This £5 million competition s...upports the development of new vaccines and vaccine technologies to combat diseases with epidemic potential in low and middle income countries (LMICs). It does this through supporting five projects seeking to develop epidemiological models, tools and technologies to assist with the deployment and clinical trialling of vaccines in outbreak situations LMICs on the Development Assistance Committee (DAC) list. This competition funds the optimal Deployment of Vaccines in Outbreak Situations, in which one project has been awarded £1.5m to develop rigorous models for how priority diseases could spread in an outbreak setting. This competition also funds the development of other tools, technologies and methodologies to assist epidemiological work in outbreak settings. Under this section four projects have been awarded a total of £2.7m and include work such as an electronic data kit to support epidemiological research in LMICs during epidemics and anthropological work exploring vaccine deployment in LMICs during an epidemic.This competition is run through the National Institute of Health Research's Central Commissioning Facility.
more
|
0
|
12250
|
Infectious disease control
|
|
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
University, college or other t...eaching institution, research institute or think?tank
more
|
|
COVID-19
|
6567976e212eaade2e0ee28b
|
2020
|
United Kingdom
|
Department of Health and Soci...al Care
more
|
2020009773a
|
UKVN-PVD-IUK
|
3
|
Developing countries, unspecif...ied
more
|
Regional and Unspecified
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0
|
1.812966
|
0
|
0
|
0
|
1.812966
|
0
|
0
|
|
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
UK VACCINE NETWORK - PRECLINIC...AL VACCINE DEVELOPMENT COMPETITION
more
|
UK Vaccine Network - Preclinic...al Vaccine Development Competition
more
|
This £24,719,293 competition ...supports the development of new vaccines and vaccine technologies to combat diseases with epidemic potential in low and middle income countries (LMICs). It does this through supporting the preclinical development of candidate vaccines and vaccine platform technologies. This competition is run through Innovate UK.This competition has an initial funding stage, after which successful projects could apply for follow on funding to support continued development of their vaccine products. This includes early stage clinical work. Twenty two projects were supported through the first phase of the competition and seven progressed to the second stage funding. These projects include research for a Ebola Lassa Marburg vaccine, advancing a Hantavirus vaccine, a Q fever vaccine, two haemorrhagic fever vaccine projects, serological vaccine standards research, and a Crimean Congo Haemorrhagic Fever vaccine.
more
|
0
|
12250
|
Infectious disease control
|
|
|
11001
|
Central Government
|
Central Government
|
|
COVID-19
|
6567976e212eaade2e0ee28c
|
2020
|
United Kingdom
|
Department for International D...evelopment
more
|
2019000556a
|
300343-102
|
3
|
Developing countries, unspecif...ied
more
|
Regional and Unspecified
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
B03
|
0
|
0.179556
|
0
|
0
|
0
|
0.179556
|
0
|
0
|
|
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
WORLD HEALTH ORGANISATION - S...PECIAL PROGRAMME IN RESEARCH AND TRAINING IN TROPICAL DISEASES (TDR) (2018-2022)
more
|
World Health Organisation - S...pecial Programme in Research and Training in Tropical Diseases (TDR) (2018-2022)
more
|
To contribute to research lead...ing to improvements in (i) health systems and policy, (ii) infectious disease knowledge, solutions and implementation of strategies, iii) research to improve sexual and reproductive health
more
|
NTDs
|
12182
|
Medical research
|
|
|
41143
|
World Health Organisation - co...re voluntary contributions account
more
|
World Health Organisation - co...re voluntary contributions account
more
|
|
COVID-19
|
6567976e212eaade2e0ee28d
|
2020
|
United Kingdom
|
Department of Health and Soci...al Care
more
|
2020009666
|
16_136_33
|
3
|
Developing countries, unspecif...ied
more
|
Regional and Unspecified
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
D02
|
0
|
3.013386
|
0
|
0
|
0
|
3.013386
|
0
|
|
|
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
NIHR GLOBAL HEALTH RESEARCH UN...IT ON TACKLING INFECTIONS TO BENEFIT AFRICA (TIBA)
more
|
NIHR Global Health Research Un...it on Tackling Infections to Benefit Africa (TIBA)
more
|
A UK and low- and middle-incom...e country (LMIC) partnership that aims to reduce the burden of infectious diseases by strengthening health systems in Africa.
more
|
0
|
12182
|
Medical research
|
|
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
University, college or other t...eaching institution, research institute or think?tank
more
|
|
|
6567976f212eaade2e0ee28e
|
2020
|
United Kingdom
|
Department of Health and Soci...al Care
more
|
2020009668
|
16_136_46
|
3
|
Developing countries, unspecif...ied
more
|
Regional and Unspecified
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
D02
|
0
|
4.05991
|
0
|
0
|
0
|
4.05991
|
0
|
|
|
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
NIHR GLOBAL HEALTH RESEARCH UN...IT ON MUCOSAL PATHOGENS (MPRU)
more
|
NIHR Global Health Research Un...it on Mucosal Pathogens (MPRU)
more
|
A UK and low- and middle-incom...e country (LMIC) partnership that aims to optimise control of mucosal pathogens causing pneumonia, meningitis and sepsis in young children.
more
|
0
|
12182
|
Medical research
|
|
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
University, college or other t...eaching institution, research institute or think?tank
more
|
|
|
6567976f212eaade2e0ee28f
|
2020
|
Germany
|
Foreign Office
|
2020009679
|
6615201
|
8
|
Ghana
|
South of Sahara
|
LMICs
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0.002659
|
0.002659
|
0
|
0
|
0.002659
|
0.002659
|
|
0.002659
|
|
0
|
COVID-19
|
COVID-19 Personal Protective E...quipment
more
|
100
|
COVID-19 EQUIPMENT AID OF THE ...KYEREH FOUNDATION IN THE GREATER ACCRA REGION, GHANA
more
|
Covid-19 Equipment Aid of the ...Kyereh Foundation in the Greater Accra Region, Ghana
more
|
Purchase of - 500 Re-Usable Fa...ce Masks, 500 Units Hand Sanitizer, 10 Thermometer, 50 Packages of Paper Tissue, 30 Victoria Buckets, 300 Face Shields - for the following places Breman Kuntanase, Ewusiem, Abehenase and Akurakese all in the Asikuma odoben brakwa district in Bono Region and Maranatha JHS, Sege Community JHS both in Ada.
more
|
|
12264
|
COVID-19 control
|
|
I.2.b. Basic Health
|
23000
|
Developing country-based NGO
|
Developing country-based NGO
|
|
COVID-19
|
6567976f212eaade2e0ee290
|
2020
|
United Kingdom
|
Department of Health and Soci...al Care
more
|
2020009695
|
17_63_110
|
3
|
Developing countries, unspecif...ied
more
|
Regional and Unspecified
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
D02
|
0
|
0.604175
|
0
|
0
|
0
|
0.604175
|
0
|
|
|
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
NIHR GLOBAL HEALTH RESEARCH GR...OUP ON IMPROVING THE MANAGEMENT OF ACUTE BRAIN INFECTIONS
more
|
NIHR Global Health Research Gr...oup on Improving the Management of Acute Brain Infections
more
|
A UK and low- and middle-incom...e country (LMIC) partnership that aims to improve the diagnosis of acute brain infections in adults and children, guide treatment and improve outcomes, while developing research capacity and establishing a broad network of hospitals interested in studying brain infections.
more
|
0
|
12182
|
Medical research
|
|
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
University, college or other t...eaching institution, research institute or think?tank
more
|
|
|
6567976f212eaade2e0ee291
|
2020
|
United Kingdom
|
Department for International D...evelopment
more
|
2016001114b
|
204765-103
|
3
|
Developing countries, unspecif...ied
more
|
Regional and Unspecified
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0
|
1.610913
|
0
|
0
|
0
|
1.610913
|
0
|
0
|
|
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
RESEARCH ON DISEASE OUTBREAKS,... TO INFORM MORE EFFECTIVE PREPAREDNESS AND RESPONSE, IN PARTNERSHIP WITH WELLCOME
more
|
Research on Disease Outbreaks,... to inform more effective preparedness and response, in partnership with Wellcome
more
|
Epidemics and Global Health Se...curity Research Programme (Epidemics and GHS) - This programme will accelerate research and development for disease outbreaks (such as COVID19, Ebola etc) with the goal of preventing and tackling epidemics, saving lives and improving global health security. The programme will support the development of new vaccines, diagnostics and treatments for epidemic diseases and provide better evidence about outbreak diseases, to inform more effective preparedness and response activities.
more
|
0
|
12182
|
Medical research
|
|
|
21000
|
International NGO
|
INTERNATIONAL NGO
|
|
|
6567976f212eaade2e0ee292
|
2020
|
United Kingdom
|
Department for International D...evelopment
more
|
2017000335b
|
204765-104
|
3
|
Developing countries, unspecif...ied
more
|
Regional and Unspecified
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
B03
|
0
|
0.810834
|
0
|
0
|
0
|
0.810834
|
0
|
0
|
|
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
WHO (WORLD HEALTH ORGANISATION...) BLUEPRINT TO ACCELERATE RESEARCH & DEVELOPMENT FOR DISEASE OUTBREAKS
more
|
WHO (World Health Organisation...) Blueprint to Accelerate Research & Development for Disease Outbreaks
more
|
Epidemics and Global Health Se...curity Research Programme (Epidemics and GHS) - This programme will accelerate research and development for disease outbreaks (such as COVID19, Ebola etc) with the goal of preventing and tackling epidemics, saving lives and improving global health security. The programme will support the development of new vaccines, diagnostics and treatments for epidemic diseases and provide better evidence about outbreak diseases, to inform more effective preparedness and response activities.
more
|
0
|
12182
|
Medical research
|
|
|
41143
|
World Health Organisation - co...re voluntary contributions account
more
|
World Health Organisation - co...re voluntary contributions account
more
|
|
|
65679770212eaade2e0ee293
|
2020
|
United Kingdom
|
Department for International D...evelopment
more
|
2017000718b
|
300342-101
|
3
|
Developing countries, unspecif...ied
more
|
Regional and Unspecified
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
D02
|
0
|
3.602636
|
0
|
0
|
0
|
3.602636
|
0
|
0
|
|
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
CAUSES OF FEVER STUDY: TO IDEN...TIFY THE PATHOGENS WHICH CAUSE FEVERS, TO TREAT THEM EARLY, TO IDENTIFY UNDERLYING LEVELS OF RESISTANCE TO EXISTING TREA
more
|
Causes of fever study: to iden...tify the pathogens which cause fevers, to treat them early, to identify underlying levels of resistance to existing trea
more
|
This programme in the Ross Fun...d Portfolio (which focusses on neglected tropical diseases, diseases of emerging resistance and diseases of epidemic potential) aims to build the evidence based on effective interventions and delivery mechanisms to tackle infectious diseases in low and middle income countries. The research programmes will take an integrated and multi-disciplinary approach to help DFID and the development community better understand what works most effectively to tackle infectious diseases, building upon the existing evidence base. The research addresses a number of core themes, including delivery through health systems, value for money of interventions, vulnerable groups, gender and building evidence on interventions in a range of contexts including (but not limited to) fragile and conflict affected states.
more
|
0
|
12182
|
Medical research
|
|
|
22000
|
Donor country-based NGO
|
Donor country-based NGO
|
|
|
65679770212eaade2e0ee294
|
2020
|
United Kingdom
|
Department for Business, Innov...ation and Skills
more
|
2020008269
|
BBSRC_NS_BB/M024156/1
|
3
|
Developing countries, unspecif...ied
more
|
Regional and Unspecified
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0
|
0.017085
|
0
|
0
|
0
|
0.017085
|
0
|
0
|
0
|
0
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
SPHINGOLIPID BIOSYNTHESIS IN T...HE PARASITIC APICOMPLEXAN PROTOZOA: DIVERGENT ENZYMES IN KEY HOST:PATHOGEN INTERACTIONS
more
|
Sphingolipid biosynthesis in t...he parasitic apicomplexan protozoa: divergent enzymes in key host:pathogen interactions
more
|
In the developing world apicom...plexan disease is a major cause of economic loss through their effects on both human health and agricultural production. This project will identify potential drug targets in the Apicomplexa, parasites of humans (e.g. toxoplasmosis and malaria) and economically important animals (e.g. toxoplasmosis and coccidiosis).
more
|
0
|
12182
|
Medical research
|
|
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
University, college or other t...eaching institution, research institute or think?tank
more
|
|
|
65679770212eaade2e0ee295
|
2020
|
United Kingdom
|
Department for Business, Innov...ation and Skills
more
|
2020008257
|
BBSRC_NS_BB/N004574/1
|
3
|
Developing countries, unspecif...ied
more
|
Regional and Unspecified
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0
|
0
|
0.0135785
|
0
|
0
|
0
|
0.027157
|
0
|
0
|
0
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
50
|
DEFINING THE MOLECULAR BASIS O...F HOST-PATHOGEN INTERACTION IN BOVINE TB
more
|
Defining the molecular basis o...f host-pathogen interaction in bovine TB
more
|
This project will further our ...understanding of a number of aspects of bovine tuberculosis. New approaches to disease control are urgently needed, and this project offers new avenues to the development of both improved vaccines (such as liveattenuated vaccines), as well as improved diagnostics.
more
|
0
|
31182
|
Agricultural research
|
|
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
University, college or other t...eaching institution, research institute or think?tank
more
|
|
|
65679770212eaade2e0ee296
|
2020
|
Germany
|
Foreign Office
|
2020009756
|
6615357
|
8
|
Bolivia
|
South America
|
LMICs
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0.027123
|
0.027123
|
0
|
0
|
0.027123
|
0.027123
|
|
0.027123
|
|
0
|
Classified as not health-speci...fic activity
more
|
|
100
|
COVID-19 - PURCHASE OF FOOD AN...D SEEDS FOR FAMILIES AFFECTED BY DROUGHT, FOREST FIRES AND COVD-19
more
|
Covid-19 - Purchase of food an...d seeds for families affected by drought, forest fires and COVD-19
more
|
Purchase of food and seeds to ...restore production capacity and food security to 899 families in 24 communities in the municipality of San Ignacio de Velasco
more
|
|
12240
|
Basic nutrition
|
|
I.2.b. Basic Health
|
23000
|
Developing country-based NGO
|
Developing country-based NGO
|
|
COVID-19
|
65679771212eaade2e0ee297
|
2020
|
United Kingdom
|
Department of Health and Soci...al Care
more
|
2020009749
|
GAMRIF-WP1-UK-CHINA
|
3
|
Developing countries, unspecif...ied
more
|
Regional and Unspecified
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0
|
3.480425
|
0
|
0
|
0
|
3.480425
|
0
|
|
|
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
GLOBAL ANTIMICROBIAL RESISTANC...E INNOVATION FUND (GAMRIF) – UK-CHINA: INNOVATION AND COLLABORATION TO TACKLE ANTIMICROBIAL RESISTANCE (AMR)
more
|
Global Antimicrobial Resistanc...e Innovation Fund (GAMRIF) – UK-China: Innovation and Collaboration to tackle antimicrobial resistance (AMR)
more
|
Through the Global AMR Innovat...ion Fund (GAMRIF), the UK Department of Health and Social Care's (DHSC) UK-China research competition supports new innovations to address antimicrobial resistance (AMR) in both humans and animals, which together constitute a significant threat to human health. Successful projects are a partnership of UK companies and research organisations with Chinese companies and research organisations. £10 million of UK aid funding was awarded to UK researchers through DHSC's delivery partner Innovate UK, with the Chinese Ministry of Science and Technology (MoST) providing funding for the Chinese partners who will receive up to a total of 60 million RMB. The research outputs of these partnerships are intended to benefit people in low- and middle-income countries (LMICs) around the world.This is a UK-China collaboration, where UK researchers are funded by the UK government and the Chinese by the Chinese government. It supports innovative and unique research and development projects benefitting people in LMICs, that neither country could carry out on their own. The UK does not spend ODA in China for this partnership, apart from on events which are held in China.The aim of this partnership is to support novel research projects that will develop the use of cutting-edge solutions to tackle critical issues of AMR in humans and animals and other LMICs. This includes solutions that will: - explore opportunities from Traditional Chinese Medicine for the treatment and/or prevention of infectious diseases in humans and animals - advance the discovery of new agents, including small molecule drugs, vaccines, antibodies and other biological products - identify new agents that increase feed energy conversion in livestock without using antibiotics or hormones - use modelling and clinical studies to maximise the clinical utility of current antibiotics - improve diagnostic capabilities for the diagnosis, treatment selection and surveillance of bacterial infections and antibacterial resistanceThe primary purpose of this activity is for the benefit of LMICs. The outputs from this activity can be applied/adapted for other DAC-list country/countries and therefore would benefit a wider geographical region.
more
|
0
|
12250
|
Infectious disease control
|
|
|
11001
|
Central Government
|
Central Government
|
|
|